Evidence map›Paper›PMID 28631100›Full record

ArticlePsychopharmacology2017

Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse.

Thomas Freret, Véronique Lelong-Boulouard, Pierre Lecouflet, Katia Hamidouche, François Dauphin, Michel Boulouard

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Combinatorial targeting of NMDARs and 5-HTAlzheimer's research & therapy · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Distinct Co-Modulation Rules of Synapses and Voltage-Gated Currents Coordinate Interactions of Multiple Neuromodulators.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Thomas FreretNormandie University, UNICAEN, INSERM, COMETE, 14000, Caen, France. thomas.freret@unicaen.fr.
Véronique Lelong-BoulouardNormandie University, UNICAEN, INSERM, COMETE, 14000, Caen, France.
Pierre LecoufletNormandie University, UNICAEN, INSERM, COMETE, 14000, Caen, France.
Katia HamidoucheNormandie University, UNICAEN, INSERM, COMETE, 14000, Caen, France.
François DauphinNormandie University, UNICAEN, INSERM, COMETE, 14000, Caen, France.
Michel BoulouardNormandie University, UNICAEN, INSERM, COMETE, 14000, Caen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimIt is widely assumed that the upcoming therapeutics for Alzheimer's disease will require to act on more than one target to be effective. We investigated here whether a combination of the nicotinic receptor allosteric modulator/cholinesterase inhibitor galantamine can act synergistically with the type 4 serotonin receptor (5-HT4R) partial agonist, RS-67333, to counterbalance deficits in short- and long-term memory. To select sub-efficacious doses of both drugs, dose-response studies were first performed on the scopolamine-induced deficits of spontaneous alternation in the Y-maze task and of acquisition and retrieval processes in a passive avoidance task.

resultFor spontaneous alternation behavior, combination of 1 mg/kg galantamine and 0.5 mg/kg RS-67333 fully reversed the deficit. In the passive avoidance task, no sub-efficacious doses could be found in the retention paradigm, but a beneficial effect of the association has been demonstrated in the acquisition paradigm.

conclusionMnesic effects of galantamine can be thus potentiated by activation of 5-HT4R. Such a combination treatment might (1) strengthen symptomatic relief, (2) attenuate adverse effects given the lower doses of each compound required, and (3) afford a disease-modifying effect given the known action of 5-HT4R on amyloidogenesis cascade.

Indexed as

Allosteric RegulationAlzheimer DiseaseAniline CompoundsAnimalsCholinesterase InhibitorsGalantamineMaleMemory DisordersMiceNicotinic AntagonistsPiperidinesReceptors, NicotinicReceptors, Serotonin, 5-HT4ScopolamineSerotonin 5-HT4 Receptor AgonistsAniline CompoundsCholinesterase InhibitorsGalantamineNicotinic AntagonistsPiperidinesReceptors, NicotinicReceptors, Serotonin, 5-HT4RS 67333ScopolamineSerotonin 5-HT4 Receptor AgonistsAcetylcholinesterase inhibitorBehaviorMemoryNeurodegenerativeSerotonin

Identifiers

PMID28631100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.